

• **Name:**

Jeong-Hoon Lee

• **Current Position:**

Professor

• **Country:**

Korea

• **Educational Background:**

- Master's Degree of Medicine, Seoul National University, Korea (2007)
- Doctor's Degree of Medicine, Seoul National University, Korea (2009)

• **Professional Experience:**

- Assistant Professor, Seoul National University Hospital (2010-2016)
- Associate Professor, Seoul National University Hospital (2016-2021)
- Professor, Seoul National University Hospital (2021-present)

• **Professional Organizations:**

The Korean Association of Internal Medicine

The Korean Association for the Study of the Liver

The Korean Liver Cancer Association

The Korean Society of Gastrointestinal Endoscopy

The Asian-Pacific Association for the Study of the Liver

The European Association for the Study of the Liver

The American Association for the Study of the Liver Diseases

• **Main Scientific Publications:**

1. Adjuvant Immunotherapy with Autologous Cytokine-induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology. 2015 Jun;148(7):1383-1391. (**first author**) (IF₂₀₁₉=17.373)
2. The Discontinuation of Nucleos(t)ide Analogues Is Not Associated with A Higher Risk of HBsAg-Seroreversion after Antiviral-Induced HBsAg-Seroclearance: A Nationwide Multicenter Study. Gut. 2020 Dec;69(12):2214-2222. (**corresponding author**) (IF₂₀₁₉=19.819)

3. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. *Hepatology*. 2017 Nov;66(5):1556-1569. (**corresponding author**) (IF₂₀₁₉=14.679)
4. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. *J Hepatol*. 2019 Jun;70(6):1093-1102. (**first & corresponding author**) (IF₂₀₁₉=20.582)
5. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study. *Clin Cancer Res*. 2013 Aug;19(15):4218-4227. (**corresponding author**) (IF₂₀₁₉=10.107)
6. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. *Ann Surg*. 2016 May;263(5):842-850. (**first author**) (IF₂₀₁₉=10.130)
7. Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B. *Hepatology*. 2020 Oct. (**first author**) [*Advance Online Publication*] (IF₂₀₁₉=14.679)
8. Entecavir Plus Pegylated Interferon and Sequential HBV Vaccination Increases HBsAg Seroclearance: A Randomized Controlled Proof-of-Concept Study. *Clin Infect Dis*. 2020 May (**first author**) [*Advance Online Publication*] (IF₂₀₁₉=8.313)
9. Empirical Treatment with Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. *Clin Gastroenterol Hepatol*. 2021 May;19(5):976-986. (**corresponding author**) (IF₂₀₁₉=8.549)
10. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemo-embolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. *Radiology*. 2014 Jun;271(3):909-918. (**corresponding author**) (IF₂₀₁₉=7.931)